glp-1 constipation class action in kentucky lawsuit Intel Microbiota-driven gut-brain signaling underlies antidepressant

Emerging evidence also suggests potential cardiovascular benefits, with some injectable GLP-1 receptor agonists demonstrating reduced risk of major adverse cardiovascular events in people with established cardiovascular disease

GLP-1 medications such as semaglutide have shifted from diabetes-only treatments to recognized weight loss therapies for people across the metabolic spectrum

European Neuropsychopharmacology , 83, 10-19

2024;7(11):e24453092445309

Extended-release formulations may be considered to improve tolerability and compliance in those who have difficulty adhering to a twice-daily immediate-release regimen